Adaptive Servo-ventilation (ASV) Therapy Suggests Positive Cardiovascular Outcomes for People with Sleep-Disordered Breathing and Heart Failure With Preserved Ejection Fraction In Phase II Study
Top-line results from ResMed-sponsored CAT-HF study announced at 2016 annual Heart Failure Congress
Florence, Italy – May 22, 2016 – ResMed (NYSE: RMD) today announced primary results
The results of the trial were presented as a late-breaking presentation by Christopher M. O’Connor, M.D., the principal investigator of the study and Chief Executive Officer and Executive Director of the Inova Heart and Vascular Institute.
Cardiovascular outcomes were defined in the trial by a Global Rank Score primary endpoint that included survival free from cardiovascular hospitalization and improvement in functional capacity as measured by the six-minute walk distance.
The overall study results were neutral (based on a hazard ratio [HR] =1.07, 95 percent confidence interval [95% CI] = (0.75, 1.51), p-value = 0.717). However, a pre-specified subgroup analysis showed a statistically significant improvement in the primary endpoint for people with heart failure with preserved ejection fraction who have sleep-disordered breathing (based on a HR = 0.38, 95% CI = (0.15, 0.98), p-value = 0.045).
“These results are important because they are the first to show that addressing sleep-disordered breathing with ASV therapy may improve cardiovascular outcomes for people with preserved ejection fraction heart failure,” said ResMed Chief Medical Officer, Glenn Richards, M.D. “We look forward to fully analyzing the results to better understand the role of addressing sleep-disordered breathing in patients with heart failure to determine who would be appropriate candidates for ASV therapy.”
Chronic heart failure occurs when the heart does not pump enough blood to meet the needs of the body. When the heart contracts normally but does not relax sufficiently to fill the chamber with enough blood, it is classified as heart failure with preserved ejection fraction. If the heart cannot contract to pump enough blood, it is heart failure with reduced ejection fraction. Approximately half of
CAT-HF is the second randomized controlled ResMed-sponsored study examining the role of treating sleep-disordered breathing in people with heart failure. Last year, results were published from a Phase IV study known as SERVE-HF that showed ASV therapy should not be used for patients with predominant central sleep apnea and symptomatic chronic heart failure with reduced ejection fraction.
CAT-HF was designed to address a different scientific question of whether cardiovascular outcomes could be improved with ASV therapy after hospitalization for sudden worsening symptoms for people with both preserved and reduced heart failure who also have either obstructive or central sleep apnea.
ResMed is researching how addressing sleep-disordered breathing may help people with cardiovascular diseases, from hypertension and coronary artery
About Sleep-disordered Breathing
Sleep-disordered breathing encompasses a spectrum of breathing problems during sleep. The two most common types of sleep apnea, a condition that results in repetitive pauses in breathing during sleep, are obstructive sleep apnea and central sleep apnea.
Obstructive sleep apnea is a sleep disorder in which the throat muscles relax, block the airways and stop the flow of breath during sleep. Central sleep apnea is a sleep disorder in which the brain does not transmit the “breathe” signal to the muscles that control breathing during sleep.
In either situation, the lack of oxygen causes the person to wake up to catch their breath and start breathing again, interrupting continuous sleep. This may occur multiple times in an hour.
Sleep-disordered breathing is found more commonly in patients with heart failure than it is in the general population, and people with heart failure often report poor sleep as a symptom.
CAT-HF is a randomized controlled trial that evaluated whether adding adaptive servo-ventilation (ASV) to optimized medical therapy could improve cardiovascular outcomes at six months for people with
The primary endpoint was cardiovascular outcomes measured as a Global Rank Score of six-minute walk distance, hospitalizations due to cardiovascular issues and death. The study also assessed changes in functional parameters, arrhythmias, biomarkers, quality of life (QoL), and sleep and breathing.